Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





LumiraDx Demonstrates Fast, High Performance, Portable POC Diagnostic Solution

By LabMedica International staff writers
Posted on 24 May 2023

LumiraDx (London, UK) is presenting its innovative diagnostic solutions at this year's WorldLab-EuroMedLab in Rome, Italy, 21-25 May, including its LumiraDx Platform which is designed to perform multiple tests on one single instrument wherever needed. More...

The LumiraDx Platform is similar to a portable laboratory, compact yet capable of delivering lab-grade results in a variety of care settings, thereby bringing clinical decision-making closer to the patient. This rapid, high-performing, portable point-of-care (POC) diagnostic solution employs active microfluidic technology, providing results for a range of analytes, including NT-proBNP, HbA1c, and CRP, within minutes. The single, portable instrument offers a simple and uniform workflow for all tests and is user-friendly - all that's needed is to follow the on-screen video instructions for high-sensitivity results in minutes.

The LumiraDx Platform serves as a cost-effective replacement for multiple POC systems. Its compact, lightweight design, combined with actively controlled microfluidic test strips and secure connectivity, yields lab-grade results in a matter of minutes. Both the device and test strip employ several analytical electronic quality control measures to ensure the test's integrity and validity, with automated functionality checks and test strip performance controls being conducted throughout the test's operational stages. Regardless of whether healthcare professionals are using direct fingerstick or swab methods, the LumiraDx Platform's 'easy to use' test workflow employs 'easy to retrieve' small sampling directly at the patient's side.

With a pipeline of over 30 assays, LumiraDx's POCT menu is primarily focused on some of the most commonly diagnosed or managed conditions, including coagulation disorders, infectious disease, cardiovascular conditions, and diabetes. By integrating multiple technologies and sample types into one device, the LumiraDx Platform facilitates the continued expansion of a comprehensive test menu for conditions diagnosed and managed in community-based healthcare settings.

Related Links:
LumiraDx 


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Automatic Western Blot Analyzer
Tenfly Phoenix Blot Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.